
Downloaded from: http://researchonline.lshtm.ac.uk/14002/

DOI:

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
latency between putative infection or insult and the emergence of psychotic symptoms complicates establishing direct links. While most reports have been ecologic studies without confirmed maternal infection, Brown et al. (10) found that 20.4% of persons with a documented in utero exposure to rubella developed an adult schizophrenia spectrum disorder. Experimentally, lymphocytic choriomeningitis virus infection in a neonatal rat model produces some latent changes similar to those of schizophrenia, e.g., hippocampal atrophy and impaired inhibitory GABA neurotransmission (11); blocking IL-1 partially attenuates the hippocampal cell loss. Inflammatory cytokine responses, perhaps amplified by immunogenetic abnormalities, may be a common thread linking intrapartum infections and noninfectious gestational and obstetric complications to neurodevelopmental disorders (12).

**Keys to the Future**

A continuum from acute infection to chronic disease exists, and each stage is an opportunity to prevent or minimize an avoidable fraction of chronic disease—that resulting from infectious disease. Crucial steps include identifying infectious etiologies and cofactors, determining persons (including women) at risk for infection or outcome, and implementing measures that minimize chronic sequelae. Research incorporating longitudinal studies that precede clinical disease must support evidenced-based conclusions and actions. The benefits to women could be substantial.

**Siobhán O’Connor,**† **DeLisa Fairweather,**‡ **Brad D. Pearce,**‡ and **Sonja Rasmussen**†

*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Johns Hopkins University, Baltimore, Maryland, USA; and ‡Emory University School of Medicine, Atlanta, Georgia, USA

**References**


Audio tapes of all sessions are available for purchase from Conference Archives, 239 Main Street, Suite 300, Johnstown, Pennsylvania 15901; telephone: 866-316-3289 or at http://www.conferencearchives.com/cgi-bin/caistore/CDR040207.html

**Disproportionate Impact of Sexually Transmitted Diseases on Women**

Worldwide, sexually transmitted diseases (STDs) and HIV affect women more than men. This gender differential is greater in developing countries than in industrialized countries, and biological, social, cultural, and economic factors all contribute to the gender differential in STD/HIV. Larger mucosal surface area, microlesions caused during sex (particularly forced sex), and the presence of more HIV in semen than in vaginal secretions all contribute to the gender differential in STD/HIV. Culturally, men are expected to have multiple sex partners, and women may risk abuse or suspicion of infidelity if they refuse sex or request protection. Financial and material dependence on men renders women economically more vulnerable to STDs and HIV. Often women are under pressure to find a husband or bring home money, which in the absence of viable alternatives leads them into sex work. Effective prevention of STDs and HIV necessitates large-scale social,
cultural, and economic changes and female-controlled prevention, such as microbicides.

Sevgi O. Aral,* Sarah Hawkes,† Ann Biddlecom,‡ and Nancy Padian§
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †London School of Hygiene and Tropical Medicine, London, United Kingdom; ‡Alan Guttmacher Institute, New York City, New York, USA; and §University of California at San Francisco, San Francisco, California, USA

Address for correspondence: Sevgi Aral, Division of STD Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E02, Atlanta, Georgia 30333, USA; fax: 404-639-8608; email: soa1@cdc.gov

Impact of HIV on Women in the United States

In the United States, AIDS was first reported in women in 1981 (1), and the percentage of AIDS cases in women has continued to increase, accounting for an estimated 26% of new AIDS diagnoses in 2002 (2). Since 1998, deaths among women with AIDS in the United States have remained stable at an estimated 4,000 (2).

Epidemiologic Features of HIV in Women, United States

Data from 29 states with confidential name-based HIV reporting since 1998 were used to describe the status of HIV disease among women from 1999 through 2002. HIV diagnoses were defined as diagnoses of HIV infection regardless of AIDS diagnosis status. This diagnosis includes persons with a diagnosis of HIV infection only, HIV infection and later AIDS diagnosis, or concurrent diagnoses of HIV infection and AIDS.

From 1999 through 2002, an estimated 101,872 HIV diagnoses were reported from 29 states: 72,007 (70.7%) in men and 29,865 (29.3%) in women. Among women, 71.9% were non-Hispanic blacks, 18.2% were non-Hispanic whites, 8.4% were Hispanics, 0.6% were American Indian/Alaska Natives, and 0.4% were Asian/Pacific Islanders. The two principal modes of HIV exposure for women were heterosexual contact and injection drug use, accounting for 77.7% and 20.5% of diagnoses among women, respectively. Women were diagnosed with HIV at younger ages than men. For the 4-year period, 31.3% of women with HIV were in the 13- to 29-year age group compared with 19.9% of men in the same age group. HIV diagnosis rates were consistently higher among non-Hispanic black women compared with women from other racial and ethnic groups for all 4 years.

Prevention Strategies for Women

In 2003, the Centers for Disease Control and Prevention (CDC) introduced the Advancing HIV Prevention (AHP) initiative (3). AHP aims to reduce barriers to early diagnosis of HIV infection, increase access to quality medical care and treatment, and provide ongoing prevention services for persons living with HIV. AHP incorporates four priority strategies: make voluntary HIV testing a routine part of medical care, implement new models for diagnosing HIV infections outside of the medical settings, prevent new infections by working with persons diagnosed with HIV and their partners, and decrease perinatal transmission.

Clinical Care of Women with HIV

HIV-infected women may be at increased risk for medical problems and metabolic changes. Studies have shown that HIV-positive women were more likely to develop genital warts and cervical intraepithelial neoplasia (4) and were at increased risk for viral infections (5). According to one study, HIV-positive women were 80% more likely to be anemic than HIV-positive men (6). Compared with HIV-negative controls, women with HIV were more likely to have elevated triglycerides and insulin levels (7) and decreased bone mineral density (8).

Determining when to initiate antiretroviral therapy for HIV-infected women is based on CD4+ T cell count (9). Because no gender difference exists for initiating or applying antiretroviral drug regimens, the guidelines for treating women are the same as those for treating men. Overall, drug efficacy does not differ by gender in randomized clinical trials.

For many reasons, women with HIV may avoid HIV testing and care. Often, women may be stigmatized and endure discrimination because of their HIV status. Women are often the primary caregivers for other family members, which may lead to avoiding or delaying testing and care. Economic dependence on a spouse or significant other may also play a role in whether a woman seeks testing and care. Mistrust of the healthcare system may also exist. Depression or domestic violence may also affect a woman's ability to seek needed care for HIV infection.

Incorporating HIV Prevention into Medical Care

In 2003, CDC, the Health Resources and Services Administration, National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America issued recommendations to assist clinicians in integrating HIV prevention into primary care for HIV-infected persons. Providers are encouraged to deliver brief prevention messages during primary care visits, screen for HIV risk behaviors and sexually transmitted disease, pro-